In a new report in New England Journal of Medicine, scientists claim they have cured advanced skin cancer for the first time using the patient's own cells cloned outside the body

 

The report states that the 52-year-old man involved was free of melanoma two years after treatment. The 52-year-old man had advanced melanoma which had spread to the lungs and lymph nodes.

 

In the US researchers report to the New England Journal of Medicine, it was claimed that they took cancer-fighting immune cells, made five billion copies, then put them all back.

 

Even though it is an exiting new development in the treatment of cancer scientists in the UK warned that further trials would need to be done to prove how well the treatment worked.

 

The body's immune system plays a significant role in the battle against cancer, and doctors have been looking for ways to boost this tumour-killing response.

 

This is the work of scientists at the Fred Hutchinson Cancer Research Center in Seattle who concentrated on a type of white blood cell called a CD4+ T cell.

 

They were able to select CD4+ T cells from a sample of the man's white blood cells, which had been specifically primed to attack a chemical found on the surface of melanoma cells.

 

These CD4 +T cells were then multiplied in the laboratory, and put back in their billions to see if they could mount an effective attack on the tumours.

 

The subsequent scans from follow-up of the same patient two months later showed the tumours had disappeared, and after two years, the man remained disease-free.

 

The new cells persisted in the body for months after the treatment.

 

Even while claiming this as a world first, the study authors pointed out that their technique applied only to a patient with a particular type of immune system and tumour type, and could work for only a small percentage of people with advanced skin cancer.

 

The project leader Dr Cassian Lee siad "For this patient we were successful, but we would need to confirm the effectiveness of therapy in a larger study."

 

Professor Karol Sikora, a cancer expert at Imperial College in London, described the research as "pretty exciting" with potentially wide application.

He said the researchers had focused on melanoma because the disease was well understood compared with other cancers, but other cancers could potentially be targeted.

He said: "I think we will be able to harness the power of the immune system. Eventually we will learn how to control cancer, in other words we will suppress it.

 

"Patients will live with their cancer, and die with their cancer, but not of their cancer - it will be like diabetes today."

 

In an announcement made after the report was published a spokesman for Cancer Research UK also said more research would be needed, adding: "This is another interesting demonstration of the huge power of the immune system to fight some types of cancer.

 

"Although the technique is complex and difficult to use for all but a few patients, the principle that someone's own immune cells can be expanded and made to work in this way is very encouraging for the work that ourselves and others are carrying out in this field."

 

This new development of immune cloning in the treatment of cancer will certainly provide a new hope to many with already diagnosed skin cancer or other kinds of tumours.